lag525
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jun 17, 2015 (NCT02460224)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Melanoma · Phase 2
- Neoplasms · Phase 1/Phase 2
- Neuroendocrine Tumors · Phase 2
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Stomach Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
- Lymphocyte activation gene 3 proteinINHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- lag525
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03742349 | Phase 1 | Jan 31, 2019 | Novartis |
| NCT03484923 | Phase 2 | Sep 11, 2018 | Novartis |
| NCT03499899 | Phase 2 | Jul 2, 2018 | Novartis |
| NCT03365791 | Phase 2 | Jan 24, 2018 | Novartis |
| NCT02460224 | Phase 1/Phase 2 (Phase 2) | Jun 17, 2015 | Novartis |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 5 | 5 | 2 | 2015 |
1 organizations
Page 1 / 1